TAK 003

Drug Profile

TAK 003

Alternative Names: DEN1-DEN2-DEN3-DEN4 vaccine - Takeda Pharmaceuticals USA; Dengue vaccine tetravalent - Takeda Pharmaceuticals USA; DENVax™; Needle-free dengue vaccine; TAK003; TDV - Takeda Pharmaceuticals USA; Tetravalent dengue vaccine - Takeda Pharmaceuticals USA

Latest Information Update: 07 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centers for Disease Control and Prevention; Inviragen
  • Developer PharmaJet; Takeda Pharmaceuticals USA
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Dengue

Most Recent Events

  • 16 May 2018 Phase-III clinical trials in Dengue (Prevention) in United Kingdom (SC) (NCT03525119)
  • 08 May 2018 Takeda plans a phase III trial for Dengue (prevention) in the United Kingdom, (NCT03525119)
  • 28 Feb 2018 Phase-III clinical trials in Dengue (Prevention, Combination therapy) in USA (SC) (NCT03342898)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top